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Investigation performed at the Division of Plastic and Reconstructive Surgery, Washington University School of Medicine, St. Louis, Missouri

➤

Life-threatening complications of long-term immunosuppression include malignancy, infection, and metabolic
disorders such as renal failure and diabetes.

➤

Up to three-fourths or more of patients on chronic immunosuppressive medications experience an infectious
complication.

➤

The hand transplants to date have had multiple episodes of acute rejection.

➤

The frequency and timing of episodes of acute rejection, even if the episodes are easily treated, are predictive of
chronic allograft dysfunction and failure.

➤

Chronic allograft rejection is not effectively treated with current immunosuppressive medications, and it has become a primary cause of long-term allograft failure.

The introduction of cyclosporine A in the early 1980s revolutionized solid organ transplantation. There were marked improvements not only in preserving graft function, but also in
prolonging patient survival following solid organ transplantation1. As the viability of transplanted organs improved, the indications for clinical transplantation expanded to include not
only acutely life-threatening conditions, but also more chronic
conditions that adversely affected longevity and quality of life.
Composite tissue allotransplantation involves the transplantation of nonvital tissues for reconstruction of deficits following trauma or tumor resection. If successful, composite
tissue allotransplantation would facilitate the recovery of lost
function through grafting of complex, disparate tissue types.
However, composite tissue allotransplantation also poses
unique challenges. Solid organs, such as the kidneys, may be
more tolerant of rejection episodes than are composite tissues,
for which the risk of rejection of one or more components is
high. Parenchymal organs may have a tremendous functional
reserve so that a substantial amount of tissue can be lost before organ function is compromised, but composite tissue allografts tend to have complex architecture with limited built-in
redundancy. Thus, while the majority of kidney function may
be lost before blood urea nitrogen or creatinine levels are elevated, comparable loss of the function of composite tissue allotransplants may have more profound consequences. In the

hand, for example, many fine anatomical components must
work together to achieve precise motor movements. Rejection
episodes that only impair nerve regeneration or result in loss
of muscle could result in irreversible loss of function.
Despite these obstacles, enthusiasm for composite tissue
allotransplantation has grown. In 1991, a composite tissue
transplantation workshop was held in Seattle, Washington, under the sponsorship of the Rehabilitation Research and Developmental Service of the Department of Veteran Affairs2.
Literature and scientific progress in this area were reviewed extensively by transplantation biologists and clinical transplantation surgeons. Ultimately, the participants at this conference
concluded that more research and clinical progress were necessary before clinical trials could be undertaken. In 1997, the first
International Symposium on Composite Tissue Allotransplantation was held at the Jewish Hospital in Louisville, Kentucky.
The scientific literature was again reviewed, and the controversy
of clinical application was extensively debated. Llull suggested
that a moratorium be placed on transplantation of the hand3,
but others thought that “the time [was] ripe to proceed with the
first human cadaveric hand transplantation.”4,5 Despite opposition from the majority of the hand surgery community, the first
hand transplants were performed in Lyon, France, and Louisville, Kentucky, in 1998, and other transplants in China, including bilateral transplants, have followed6.
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TABLE I Complications of Immunosuppressive Drugs
Toxicity
Malignant disease
Infection
Nephrotoxicity
Hypertension
Hyperlipidemia
Neurotoxicity
Diabetes
Osteoporosis
Gingival hyperplasia
Acne
Hirsutism
Alopecia
Gastrointestinal toxicity
Heme toxicity

Since 1998, hand transplantation has remained a divisive
subject in the hand surgery community7-12. The controversy centers on the need for indefinite high-dose immunosuppression
for allograft survival. While many experts identify composite
tissue allotransplantation as an important long-term goal of
hand and reconstructive surgery, there is debate surrounding
both the hand transplants already performed and the wisdom
of proceeding with future clinical trials. The controversy initially focused on whether the performance of the clinical hand
transplantations had been premature as demonstrated by existing experimental data that predicted early graft failure7,13-15. With
the success of several clinical hand transplants that have now
lasted for more than two years, the debate has shifted to potential side effects of long-term immunosuppression and the likelihood and timing of chronic rejection and graft failure. The
literature on solid organ transplantation provides insight into
these issues.
The discussion that follows will address the following
questions: What are the possible benefits of hand transplantation? What are the associated risks? In particular, what are the
sequelae of chronic immunosuppression? Can acute rejection
episodes predict chronic rejection and graft failure? What criteria can be used to determine whether there have been sufficient
preliminary studies of composite tissue allotransplantation to
justify its experimental use in patients?
Benefits of Composite
Tissue Allotransplantation
Much of the argument for composite tissue allotransplantation is based on the success of reconstruction of major defects
of the extremities with autologous tissue16. The most relevant

T H E S P E C T R U M O F C O M P L I C A T I O N S O F I M M U N O S U P P RE S S I O N :
I S T H E T I M E R I G H T F O R H A N D TR A N S P L A N T A T I O N ?

literature concerns the replantation of amputated digits and
limbs and the free transfer of analogous tissue components
(for example, toe-to-thumb transfers)17. While autologous reconstruction is a well-accepted option for the treatment of anatomical functional deficiencies of the hand, an unfavorable
amputation site or a lack of suitable tissue for replantation
may render this option impractical or impossible. In this setting, allotransplantation is likely to offer the best prospect for
functional recovery and restoration of body image. Composite
tissue allotransplantation could allow reconstruction of several specialized tissues other than the extremities, such as the
larynx18,19, the tongue20, and potentially other maxillofacial
components.
There are several theoretical benefits of hand transplantation. The anatomy of the hand is complex, and there are few
satisfactory alternatives to reconstruction with autologous tissue when replantation is not possible. With transplantation of
a cadaveric hand, the desired tissue can be procured without
donor-site morbidity and can be adapted to the needs of the
host environment. For example, an allograft can be fashioned
to make productive use of the damaged nerves, vessels, tendons, and joints proximal to the amputation level. Although
imperfect, a hand allograft would more closely replace the appearance, anatomy, and function of a native hand than would
any other available reconstruction. In addition, from a psychological standpoint, a hand transplant might counter the devastating effects on body image that can occur with loss of a hand.
Risks of Immunosuppression
The possible benefits of composite tissue allotransplantation,
particularly hand transplantation, must be weighed carefully
against the risks of indefinite immunosuppression. On the basis of clinical experience with solid organ transplantation, it
can be anticipated that the major risks include the possibility
of graft-versus-host disease and the morbidity resulting from
episodes of graft rejection6. To this list should be added certain considerations that are unique to composite tissue allotransplantation. For example, what are the psychological and
emotional ramifications of having a hand transplant that deteriorates in appearance or function, or both? The recipient of
the world’s first “successful” hand transplant, which was recently amputated because of rejection, stated that he had no
normal sensation in the hand and experienced pain and burning sensations. Signs of rejection are grossly evident as skin
erythema progresses to epidermolysis and eschar formation.
The patient became emotionally detached from the allograft
and “realized that it wasn’t my hand after all.”12,21 Perhaps a
more important question is: Should a hand transplant fail,
what does it mean to a patient to lose a hand not once, but
twice?
The complications of lifelong immunosuppression are
well defined and some are potentially life-threatening. Nonspecific immunosuppression is the only established clinical method
currently available for sustaining an allotransplant. Because
composite tissue allotransplantation involves multiple heterogeneous tissue types, some of which are highly antigenic, not
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TABLE II Infections in Transplant Recipients27
Prevalence of Infection (%)
Infection

Liver Transplant

Kidney Transplant

Heart Transplant

Lung Transplant

Bacterial

33-68

47

21-30

35-66

Cytomegalovirus

22-29

8-32

9-35

53-75

Herpes simplex virus

3-14

53

1-42

10-18

Varicella zoster virus

5-10

4-12

1-12

8-15

Candida

1-26

2

1-5

10-16

Mycelial fungi

2-4

1-2

3-6

3-19

Pneumocystis carinii pneumonia

4-11

5-10

1-8

15

jor infection developed in up to 88% (107) of 122 patients who
had undergone kidney, heart, or liver transplantation26. Infections account for a major part of postoperative morbidity after
solid organ transplants (Table II). The etiology may be bacterial, viral (cytomegalovirus, herpes simplex virus, or varicella
zoster virus) or fungal, and the prevalence of these infections
varies with the type of transplant and the degree of immunosuppression. Bacterial infections are the most common and
have been reported in 21% to 68% of transplant recipients, and
cytomegalovirus and herpes simplex virus may occur in up to
50% (or more) of patients27,28. In the early postoperative period,
infections are surgical complications and include wound infections; pneumonia; urinary tract infection; Clostridium difficile
colitis; infection at the site of a drain, an indwelling central
catheter, or another type of catheter; and a hematoma or lymphocele surrounding the graft26. Opportunistic pathogens that
are characteristic of patients who have had a transplant include
cytomegalovirus, Pneumocystis carinii, Aspergillus species, Nocardia species, Listeria monocytogenes, and Toxoplasma, and
they usually appear after the first month26. Pathogens already
present in the transplant recipient may be reactivated by immunosuppression; these include Mycobacterium tuberculosis,
Histoplasma capsulatum, Coccidioides immitis, and occult bacterial or viral infections. Chronic or latent infections that may
be transmitted through the allograft include human immuno-

only must immunosuppression be chronic, but it also must be
maintained at a high level. The outcomes associated with such a
regimen are not fully known, but a large body of literature addresses the prevalence of complications observed during treatment with immunosuppressive drugs (Table I).
When the complications are considered collectively,
lifelong immunosuppression can be throught of as a chronic
disease characterized by its own set of risks. Much as chronic
hypertension increases one’s risk of stroke or myocardial infarction, prolonged immunosuppression increases the risk of
infection, fracture, neoplasia, drug toxicity, and metabolic
derangement13,18-39. Unlike hypertension, however, chronic
immunosuppression is usually symptomatic. Patients on immunosuppressive regimens frequently experience undesirable changes in appearance or behavior22,23. Patients may also
have nausea, diarrhea, or a variety of other side effects24,25. The
morbidity of this new disease profoundly affects the quality of
life, alters the risk profile of composite tissue allotransplantation, and therefore must figure prominently in the balance of
risks versus benefits when determining whether to initiate
treatment.
Infection
The majority of patients who have had a transplant have an infection as a result of immunosuppression. In one study, a ma-

TABLE III Hypertension and Renal Dysfunction in Transplant Recipients
Prevalence of Complication (%)

Hypertension
Renal dysfunction

Liver Transplant
(at 1-5 Yr)

Heart Transplant
(at 1 Yr)

Heart Transplant
(at 5 Yr)

Lung Transplant
(at 1 Yr)

Lung Transplant
(at 5 Yr)

30-9034

6842

6842

4842

6342

65-80

13-52

14.042

12.642

17.642

Creatinine >5 mg/dL
(>442 µmol/L)

434

7.842

8.642

8.0042

14.442

Dialysis

234

1.2-4.4930,38,42

1.942-1036

1.6042

3.2042-1036

N/A

0.142

0.442

0.0042

0.742

Renal Transplant
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TABLE IV Fractures in Transplant Recipients39
Liver Transplant

Kidney Transplant

Heart Transplant

19.7 ± 14.1

15.7 ± 9.6

30.2 ± 39.4

Time between transplant and fracture* (mo)
Prevalence of fracture (%)
Men

11 (3/27)

4 (11/261)

9 (2/22)

13 (22/171)

All women
Postmenopausal women

100 (2/2)

45 (10/22)

12 (6/51)
30 (3/10)
100 (3/3)

*Mean and standard deviation.

deficiency virus, hepatitis B and C, and fungal or mycobacterial
infection27.
Hypertension and Nephrotoxicity
The neurohormonal mechanisms that lead to hypertension
and nephrotoxicity following transplantation are thought to
be similar. Factors that contribute to hypertension include altered renal vascular reactivity and vasoconstriction, increased
sympathetic tone, and sodium retention29,30. The development
of hypertension after cardiac or liver transplantation has been
reported in 60% to 90% of patients treated with cyclosporine
A, with prevalences of fifty-two of eight-five patients after
three months and thirteen of fifteen after three years in one
study31, and in 30% to 60% of patients treated with tacrolimus
(FK506), with prevalences of eighteen of twenty-eight patients
after two years32 and 327 of 710 after five years33,34. The nephrotoxicity of immunosuppressants has also been well studied
and is potentially the most serious side effect. Tacrolimus and
cyclosporine A have both been associated with impairment of
renal function. Table III shows the prevalence of renal failure
in heart and lung transplant recipients. (Data on liver and renal transplant recipients are not included to avoid confounding with hepatorenal syndrome and transplant dysfunction,
respectively.) The rate of renal dysfunction as defined by a serum creatinine level of >2 mg/dL (>176.8 µmol/L) has been
reported to be as high as 52% (ninety-seven of 187) only two
years after heart transplantation in patients being treated with
cyclosporine A35. Progression to end-stage renal failure may
occur within only five years postoperatively in up to 10% of
patients (as determined with actuarial analysis of 200 patients) treated with chronic cyclosporine-A therapy after heart
and lung transplantation36,37. The mechanisms of nephrotoxicity induced by cyclosporine A and tacrolimus are thought to

be identical. In the acute phase, renal blood flow is reduced as
a result of afferent arteriolar vasoconstriction secondary to sympathetic nerve stimulation, a relative increase in vasoconstricting
prostaglandins (especially thromboxane A2), and release of endothelin (a powerful renal vasoconstrictor). Chronically, there
is cumulative tubulointerstitial damage and fibrosis associated with arteriopathy38. In a review of the cases of forty-nine
children followed for a mean of only twenty-nine months after
a heart transplant, renal toxicity (defined with use of the same
criterion as described above) was noted in 37% (fourteen) of
thirty-eight patients taking tacrolimus as the initial primary
agent and in ten of eleven patients who had initially been
treated with cyclosporine A and then switched to tacrolimus
because of persistent side effects or rejection38.
Metabolic Disorders
The metabolic derangements associated with chronic immunosuppression take a variety of forms. Among the best studied
are the increased risk of fracture due to loss of bone density39,40
(Table IV) and the increased prevalence of hyperlipidemia and
diabetes30,34,41-45 (Table V). The specific abnormalities vary depending on the immunosuppressive regimen, with cyclosporine A, tacrolimus, and steroids being the most commonly
implicated agents. In a review of 600 patients who underwent
abdominal organ and heart transplantation, the prevalence of
fractures was increased by as much as 9% in men and 25% in
women and the prevalence was as high as 100% (five of five)
in postmenopausal women39. Overall, the relative risk, compared with National Health Interview Survey data on fracture
prevalence in the United States population, was thirteen times
higher in men forty-five to sixty-four years of age and eighteen
and thirty-four times higher in women twenty-five to fortyfour years of age and those forty-five to sixty-four years of age,

TABLE V Metabolic Complications in Transplant Recipients
Prevalence of Complication (%)
Liver Transplant
(at 1-5 Yr)

Heart Transplant
(at 1 Yr)

Heart Transplant
(at 5 Yr)

Lung Transplant
(at 1 Yr)

Lung Transplant
(at 5 Yr)

Hyperlipidemia

20-7534

40.642

43.842

12.542

20.542

Diabetes

4-2043

20.842

830-16.242

16.542

16.142
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TABLE VI Cancer in Transplant Recipients
Prevalence of Cancer (%)
Liver Transplant
(Overall)

Kidney Transplant
(Overall)

Heart Transplant
(At 1 Yr)

Post-Transplant
lymphoproliferative
disorder

1.7-1334,46,50,93

1.050,54,93,94

1.0-1342,50,54,93,95

Skin

2.297

2-65.394,96,97

Other

598

Total

1298

Lung Transplant
(at 1 Yr)

Lung Transplant
(at 5 Yr)

1.1630,42

1.8-2042,47,50,54,93

142

1.342

3-4342,52,94,96,97

0.642

3.242

394

1.242

3.242

1.442

1.642

2-2094

3.542

8.842

4.442

5.842

respectively39. The prevalence of hyperlipidemia can be as high
as 74% (146 of 198) after heart or liver transplantation34,41. The
prevalence may be somewhat higher with cyclosporine A
(74%; 146 of 198 patients) than with tacrolimus (51%; fiftythree of 103 patients), but it can be very high with either34. The
prevalence of diabetes mellitus is reported to be as high as
20% one year after heart transplantation and 16.5% one year
after lung transplantation (as determined on the basis of The
Registry of the International Society for Heart and Lung
Transplantation of 38,943 heart transplant and 2855 heartlung transplant recipients)42 and 29% after renal transplantation44. The mechanisms of these metabolic derangements
have been reviewed in detail elsewhere30,34,42,44,45.
Malignant Lesions
Recipients of organ transplants are at substantially increased
risk for the development of cancer. The relative risk of certain
types of malignant disease has been estimated to be up to 400
times that in the general population. The prevalences of different malignant lesions, organized by type of transplant, are
shown in Table VI. The most common malignant lesions seen
in transplant recipients are skin cancers, which account for
37% of post-transplant tumors (4305 of 11,483)46. The prevalence varies with the type of transplant, geographical location, and sun exposure. The prevalence of nonmelanoma skin
cancers developing within twenty years after liver transplantation is 30% in temperate climates such as the Netherlands, but
it rises to 70% (as determined with a life-table analysis of 1098
patients) in more equatorial locations such as Australia47,48.
Similarly, the prevalence twenty years after renal allografting
was reported to be 40% (as determined with a life-table analysis of 764 patients) in a Dutch study49, but the prevalence
twenty-four years after renal allografting was 66% (as determined from the Australia and New Zealand Combined Dialysis and Transplant Registry of 6596 patients) in Australia50,51.
Skin cancer was found to occur in 43% of patients (cumulative prevalence in 455 patients) ten years after cardiac transplantation in Australia52,53.
Post-transplant lymphoproliferative disorders are the second most common malignant diseases after transplantation,
but they are more troubling as the mortality rate is 50% to
80%54. The prevalence of these disorders is lower (1%) after

Heart Transplant
(at 5-10 Yr)

renal transplantation but has been reported to be as high as
20% in recipients of nonrenal allografts50. The prevalence after
lung transplantation in children has been reported to be as high
as 13% (sixteen of 128 patients), and the prevalence increases to
21% (thirteen of sixty-one) in patients with cystic fibrosis, a
common indication for lung transplantation55. The prevalence
has been found to be as high as 32% (thirteen of forty-one patients) after intestinal transplantation54,56. The increased prevalence of cancer in patients treated with immunosuppression
is thought to result from impaired immune surveillance of
aberrant cells. This weakening of the body’s defenses allows
malignant cells that would normally be destroyed in an immunocompetent individual to survive and multiply in an immunosuppressed host. Withdrawal of immunosuppression often
enables the body to control the progression of lymphoproliferative neoplasia but increases the risk of graft rejection.
Chronic Allograft Dysfunction and Rejection
The frequency and timing of acute rejections predict chronic
rejection and allograft failure. Chronic rejection is the most
prevalent cause of long-term failure of allograft organ transplantation, and its prevalence has remained unchanged despite two decades of progress in immunosuppressive therapy
and perioperative care57. Chronic rejection with loss of the allograft is seen in 52% of patients (thirteen of twenty-five) by
five years after cardiac and lung transplants42,58 and in >50%
(as determined on the basis of multicenter data from the
United Network for Organ Sharing [UNOS] and Eurotransplant) seven to eight years after renal allograft transplantation59,60. The literature on renal transplantation indicates that
the risk of chronic rejection increases threefold with one acute
rejection episode, twelvefold with two or more acute episodes, and twenty-six-fold with late rejection episodes (those
occurring more than eight weeks after transplantation)61. Experience with the first hand transplants performed in Lyon,
France, and Louisville, Kentucky, suggests that preventing
chronic rejection of composite tissue allotransplants will not
be easy. Acute rejection episodes were noted at eight, fifty-five,
and seventy-four weeks in Lyon and at four to six, eighteen to
twenty, and seventy-seven weeks in Louisville6. These frequent
and late acute rejection episodes suggest a substantial risk of
chronic allograft rejection.
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TABLE VII Scheme for Classifying Different Types of Transplant Surgery
Surgical Indications

Clinical Transplants

Life-threatening disease

Heart, lung, liver

Chronic debilitating disease

Kidney, pancreas

Functional deficit without active disease

Peripheral nerve*, limb/composite tissue, traumatic vocal cord injury18

*Nerve allotransplantation requires temporary rather than indefinite immunosuppression.

While the principal risk of hand transplantation results
from immunosuppression, the principal obstacle to functional
recovery is rejection. Because of the risk of rejection, the results
of hand transplantation may be poorer than those of hand replantation. Function must be restored for limb transplantation
to be considered a success62. The factors limiting recovery of
function are impaired nerve regeneration and loss of motor
units and sensory receptors. Composite tissue allotransplantation involves transplantation of composite tissues containing
highly antigenic properties. Nerve regeneration could theoretically be impaired in the setting of a large antigen load. In primate studies conducted in our laboratory, nerve allografts
treated with anti-CD40 ligand, an agent that blocks the costimulatory pathway between T-cells and antigen-presenting cells,
showed robust regeneration. However, addition of a skin graft
led to rejection in the same model, suggesting that one antigenic
tissue component may predispose other tissue components to
rejection63. Patients treated with nerve allotransplantation alone
require immunosuppression only for the time necessary for
host axons to traverse the allograft and reach host motor and
sensory targets. Similarly, experimental studies on acute rejection of nerve allografts have demonstrated only a very short
window of time during which immunosuppression can rescue a
nerve allograft undergoing acute rejection64. If there is an episode of acute rejection, it is only a matter of days before the
nerve allograft can no longer be rescued.
Thus, episodes of acute rejection in hand transplant recipients are more than just temporary setbacks. Even though these
acute episodes have been controlled relatively easily, the fact that
they have been frequent and that some have occurred late predicts chronic rejection and ultimate failure of the allograft.
Balancing Risks and Benefits
Risks that are considered to be acceptable in association with
solid organ transplantation are not necessarily acceptable in

association with composite tissue allotransplantation. The
benefits of each type of transplant surgery must be weighed
against the concomitant risks. Table VII shows one scheme for
classifying different types of transplant surgery. In the first
group are lifesaving transplantsfor example, heart, lung, or
liver transplants. In the second group are transplants that, although not immediately lifesaving, alleviate chronic disease
and offer the prospect of improved longevity and quality of
life. Composite tissue allotransplantations are a third group.
These transplants offer the possibility of functional improvement alone. The expected outcomes of surgery and subsequent immunosuppression differ for each of these groups, as
shown in Table VIII. While all share the morbidity of a new
disease (immunosuppression), the benefits of transplantation
lie along a continuum. Cardiac, lung, and liver transplantations are lifesaving. A pancreas transplant to a diabetic patient
or a kidney transplant to a patient with end-stage renal disease
may prolong life. Recipients of kidney transplants from living
relatives have been shown to survive longer than patients on
dialysis65. In each of these examples, solid organ transplantation has transcended the biological limits of end-organ failure.
Since composite tissue transplantation does not replace essential organs and remains experimental, a lower level of morbidity is acceptable. Also, unlike solid organ transplantation,
which has an established track record of clinical success, composite tissue allotransplantation is still experimental.
Ethical Considerations in Determining
Whether to Perform Experimental Surgery
What criteria can be used to determine whether to perform
experimental surgery? Siegler4 suggested that the six criteria
originally proposed by Moore66,67 be used for evaluating how
innovative surgical techniques might be applied to hand
transplantation. The criteria include (1) the scientific background of the innovation, (2) the skill and experience of the

TABLE VIII Risks and Benefits of Different Types of Transplant Surgery
Condition

Risks and Benefits of Transplantation

Life-threatening disease

Survival, but with chronic disease (immunosuppression), improved quality
and quantity of life

Debilitating chronic disease

Reversal or alleviation of prior chronic disease, new chronic disease (immunosuppression)

Functional deficit without active disease

Long-term outcome unknown, new chronic disease (immunosuppression)
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team (so-called field strength), (3) the ethical climate of the
institution, (4) open display, (5) public evaluation, and (6)
public and professional discussion.
These criteria address many aspects of experimental
surgerynot only the scientific underpinnings and the ethical
backdrop of the surgery, but also the practical issues of who
will perform the surgery, how and where it will be done, and
how it will be evaluated. Siegler4 concluded that the teams
working on clinical hand transplantation had satisfactorily
met these criteria, and he recommended proceeding with cadaveric hand transplant surgery in humans. However, it bears
mention that these criteria were designed as ethical standards
for the use of innovative surgery for life-threatening, otherwise untreatable conditions, specifically the use of innovative
liver transplantation at the University of Chicago68.
While criteria 2 through 6 can reasonably be extrapolated from liver transplantation to hand transplantation and
other types of composite tissue transplantation, the same does
not hold for criterion 1. The central concept in criterion 1 is
the equipoise consideration. Equipoise refers to a clinical setting in which the prospects for benefiting the patient are favorably balanced against the risk of causing unintended harm.
The threshold for undertaking innovative surgery is necessarily much higher for hand transplantation, the goal of which is
restoration of function, than for liver transplantation for the
treatment of a life-threatening condition. For hand transplantation to meet equipoise conditions, the benefits in terms of
functional improvement and enhanced quality of life from the
patient’s perspective must equal or exceed the risks of the surgery and subsequent immunosuppression.
Siegler’s4 assessment of the equipoise criterion here warrants scrutiny:
“Is it ethically acceptable to allow a patient to balance an
improvement in quality of life (such as may be obtained from
hand transplant) against the potential risk of morbidity and
mortality. . . ? Specifically, is improving the patient’s quality of
life (as determined by the patient) sufficient grounds to allow
patients to risk morbidity and mortality? The answer is clearly
‘yes’ because such trade-offs are inevitable and are not unique
to hand transplantation.”
The answer is “clearly ‘yes’,” only when benefits clearly
exceed risks. Physicians and surgeons regularly accept risk as
the necessary price of conferring future benefits. Although an
experimental treatment may provide benefit from the patient’s perspective, it is the surgeon’s responsibility to make
sure that such benefit does not exact an unacceptable cost. Before undertaking experimental surgery, it behooves us to reflect on the tenet “primum non nocere” (“first, do no harm”).
The Principle-Based Approach
to Human Experimentation
Several incentives may drive surgeons to move forward with
new techniques faster than is appropriate. Among these are
desperate patients, the patient’s or surgeon’s desire for notoriety, and institutional interest in market share. As Selzer wrote:
“In the act of surgery, the scalpel must be restrained rather
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than given its head. Holding back is the primary mode of surgery.”69 The ethical precepts derived from the Declaration of
Helsinki and from the Nuremberg trials can help to steady our
hand70,71. The Nuremberg Code advises in part:
(2) The experiment should be such as to yield fruitful
results for the good of society, unprocurable by other
methods or means of study. . . .
(3) The experiment should be so designed and based on
the results of animal experimentation. . . .
(10) During the course of the experiment the scientist
in charge must be prepared to terminate the experiment
at any stage, if he has probable cause to believe, in the
exercise of the good faith, superior skill and careful
judgment required of him that a continuation of the
experiment is likely to result in injury, disability, or
death to the experimental subject.

The following excerpts from the Helsinki Declaration
are also particularly relevant:
(1) Biomedical research involving human subjects . . .
should be based on adequately performed laboratory
and animal experimentation. . . .
(3) . . . The responsibility for the human subject must
always rest with a medically qualified person and never
rest on the subject of the research, even though the subject has given his or her consent.
(5) . . . Concern for the interests of the subject must always prevail over the interests of science and society.

Based on the principles from both Nuremberg and Helsinki, several aspects of hand transplantation raise concerns.
Both sets of principles place special emphasis on conducting
thorough animal research prior to human experimentation.
While some animal models of composite tissue allotransplantation do exist, they have shown varying levels of success13-15. Specifically, the pooled data from three primate studies indicated
that rejection had occurred in eighteen of twenty-four animals72,73. Sepsis or malignant disease developed in fifteen of
those animals, and only two of the twenty-four animals survived beyond 200 days. As Lee and Mathes pointed out, no animal studies have successfully demonstrated return of function
following limb allotransplantation7.
Both the Nuremburg Code and the Helsinki Declaration
instruct us to safeguard the welfare of the individual patient, a
responsibility that begins before surgery takes place. Principle 3
of the Helsinki Declaration suggests that the surgeon is obliged
to balance thoughtful guidance with careful attention to the patient’s needs. While it is inappropriate to impose personal values on patients, it is equally unacceptable to offer patients an
innovative treatment and then sit back in silence as he or she agonizes, alone, over a final decision. Principle 10 of the Nuremberg Code emphasizes the need to terminate an experiment
once there is indication that it may be injurious to the patient.
As Principle 5 of the Helsinki Declaration emphasizes,
human experimentation that purports to serve the “greater
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good” at the expense of the individual is not justifiable. The
long-term success of clinical hand transplantation remains
uncertain. While hand replantation sometimes results in durable recovery of function17, hand transplantation has not yet
been shown to provide such favorable outcomes. This must be
taken into account when determining whether surgery is in
the patient’s best interest.
Assessment with use of quality-adjusted life-years could
theoretically assist in decision-making regarding hand transplantation. This method provides a quantitative interpretation
of the subjective risks and benefits of a treatment. Unfortunately, in the case of hand transplantation, the principal benefits
are not certain since, as Lee and Mathes7 pointed out, long-term
survival of limb allografts has not been achieved. Whether functional recovery can be sustained long-term after human hand
transplantation is unknown. Furthermore, the psychological repercussions of a favorable or unfavorable outcome are difficult
to quantify. The world’s first “successful” hand transplant was
amputated on February 3, 2001. Among the patient’s complaints were the adverse effects of the treatment regimen, poor
hand function, deterioration of the hand’s physical appearance,
and a sense of both physical and psychic detachment from the
transplanted hand. In the wake of this treatment failure, the impact of rejection on quality of life must not be taken lightly74.
Given the morbidity associated with chronic immunosuppression and the lack of evidence supporting durable recovery of function, it would seem that additional research and
reflection are warranted before proceeding with additional
hand transplants. It seems doubtful that hand transplantation
in its current state serves the best interests of the individual
transplant recipient. How many members of the hand or
transplant surgery community would be willing to undergo a
hand transplant were they to lose one of their hands?
Future Directions
Composite tissue allotransplantation has become a source of
not only tremendous enthusiasm, but also considerable controversy. Nonetheless, composite tissue allotransplantation remains one of the great frontiers in hand and reconstructive
surgery. Progress in developing models of immune tolerance
suggests that a more promising paradigm for composite tissue
allotransplantation may be forthcoming. Immune tolerance is
a state of donor-specific immune unresponsiveness leading to
the indefinite engraftment of transplanted tissue without the
need for ongoing therapy. Strategies of tolerance induction include irradiation, donor-bone-marrow transfusion, intrathymic injection of donor cells, and antibody-based therapies.
Among the promising antibody-based therapies are T-cell
depletion, blockade of antigen recognition, blockade of adhesion molecules, and costimulation blockade. Currently, several
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tolerance-inducing strategies, including donor-bone-marrow
transfusion with immunosuppression, anti-ICAM (intercellular
adhesion molecule)-1 antibody, anti-LFA (lymphocyte functionassociated)-1 monoclonal antibody, anti-CD25 monoclonal antibody, and anti-CD40 ligand monoclonal antibody, are being
studied in clinical trials75.
Blockade of the CD40 costimulatory pathway appears to
be one of the most promising approaches and has produced
long-term donor-specific allograft survival in many experimental models with minimal toxicity76-83. Its role in the future of
transplantation seems to be as part of a combined regimen that
includes other modalities such as T-cell depletion and bonemarrow transfusion84-86. However, the enthusiasm resulting
from the efficacy of CD40L blockade in models of limb87 and
nerve allotransplantation64 must be tempered with the possibility that the potent neuroregenerative effects of tacrolimus cannot be used in combination with costimulation blockade. When
used simultaneously, calcineurin inhibitors such as tacrolimus
and cyclosporine A have been shown to abrogate the effects of
costimulation blockade in numerous models of skin and solid
organ transplantation88-92.
The universal acceptance of composite tissue allotransplantation as a safe and viable therapeutic option rests with
the reduction or elimination of the adverse effects of immune
modulation. The successful induction of donor-specific tolerance would circumvent the toxicity associated with nonspecific immunosuppression and may eliminate the potential for
chronic rejection. The result would be the safe transfer of
composite tissue allografts leading to improved functional
outcomes and reduced morbidity.
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